[The study of peptide effect in the mechanisms of angiogenesis and forming of microenvironment of the tumors in old rats].
Barykina. O P OP; Iuzhakov. V V VV; Chalisova. N I NI
Key Findings
- Vilon at 0.5 µg increased apoptosis of tumor cells in rats
- Vilon and epigene slowed sarcoma growth by causing hemorrhagic necrosis
- Authors propose vilon and epigene could be future cancer therapies, but only animal data are available
Practical Outcomes
- The findings are not actionable for biohackers yet—there’s no human dosage, safety, or protocol information. It’s an early‑stage animal result that would require extensive further testing before any real‑world use.
Summary
In a rat study, a synthetic peptide called vilon (and a related compound epigene) was given at a tiny dose and caused more tumor cells to die and slowed tumor growth, suggesting it might one day help treat cancer, but the research is only in animals and not ready for human use.
Abstract
The experiments were performed in rats with transplanted sarkoma M-1. The injections of synthetic peptide vilon at the doses 0.5 mcg sigificantly increased the apoptosis of tumor cells in the experiment as compared to the control group. So vilon has possessed the oncomodulating action on the transplanted carcinoma. The injections of epigene lead to the inhibition of the sarcoma growth due to the development of the hemorragic necrosis and apoptosis increased. The results obtained suggested that vilon and epigene are the perspective preparates in the cancer therapy.
Study Information
pubmed
2004